< Back to latest news & events

Blogs

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

January 2025

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway for the marketing authorisation of precision bred plants and animals, and derived food and feed products. Here we review the latest policy developments which shed light on what this new regulatory pathway will look like for applicants.

As a brief recap, the Act applies to animals, plants and algae, which are considered “precision bred” if their genome is altered using modern biotechnology in a stable (heritable) way that could have occurred through traditional breeding. The FSA is granted powers under the Act to establish a simplified, proportionate, and science-based regulatory pathway for the marketing authorisation of Precision Bred Organisms and food and feed produced from Precision Bred Organisms in the UK.

The FSA is currently developing this new regulatory pathway, the so-called Precision Breeding Regulatory Framework. Their Delivery Plan and Policy Update (linked below) were both updated last month, providing us with the most recent details on the practicalities of this new regulatory pathway.

Under the new pathway, organisms will first need to be confirmed as having Precision Bred Organism status by the Department for Environment, Food & Rural Affairs (Defra). This process will confirm their equivalence to traditionally bred organisms, which are not subject to premarket approval. Defra’s decision may take up to about 3 months. Only then can an application for food or feed authorisation be submitted to the FSA.

The FSA will implement a two-tiered food or feed marketing authorisation process. Tier 1 applications will be granted marketing authorisation without the need for a bespoke risk assessment. Instead, they will follow a new “lighter-touch” audit and registration process which is “greatly simplified compared to other regulated products processes”. The FSA estimates that decisions on Tier 1 applications will take two months.

Tier 2 applications, by contrast, will require a bespoke risk assessment focusing on specific safety concerns in a process that is “closely aligned with existing regimes”. The estimated timeframe for Tier 2 application decisions is significantly longer, taking 12 to 24 months depending on complexity. This complexity will be assessed by the FSA based on the novelty and scientific and risk management complexity of the application.

Applicants will need to determine the applicable tier to their product through a triage process based on a set of food safety criteria concerning novelty, nutritional quality, allergenicity, toxicity and other safety concerns. Products that raise any safety concerns will require Tier 2 approval. These concerns will presumably inform the focus of the bespoke risk assessment involved in Tier 2 applications.

The FSA estimates to receive about 18 applications per year, divided equally between the two tiers.

In short, the FSA is setting up a simpler faster (2 month) Tier 1 application process for the food and feed marketing authorisation of Precision Bred Organisms, alongside a bespoke slower (1-2 year) Tier 2 application process to tackle specific safety concerns. Questions remain about the exact triage criteria that will decide the tier of an application, with detailed guidance for applicants expected to be released soon.

Follow our Agritech Thymes blog for further developments.

Further reading

https://www.food.gov.uk/board-papers/precision-breeding-delivery-plan

https://www.food.gov.uk/board-papers/policy-development-precision-breeding


This article was written by Trainee Patent Attorney Aron Ferenczi

Latest updates

Avoiding Legal Pitfalls: The Notting Hill Bag Company's Costly Mistake

[2025] EWHC 1793 (IPEC) – Natasha Courtenay-Smith and Notting Hill Bag Company Limited v The Notting Hill Shopping Bag Company Limited, Nangialai Takanai, The Notting Hill Shopper Bag Ltd, Ehsanullah …

Read article
Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article